- Biotech Growth Trust said it boosted its net asset value per share by 20% in the first half, though it still underperformed its benchmark.

This Nasdaq Biotechnology Index, measured in sterling terms, rose 23% over the same period.

'The company's strong absolute performance can be attributed to renewed investor interest in the sector,' the fund said.

'Underperformance relative to the benchmark was chiefly caused by emerging biotechnology positions, such as Puma Biotechnology and Clovis Oncology, that significantly underperformed the index.'

At 3:03pm: [LON:BIOG] Biotech Gwth share price was -10p at 710p

Story provided by